Tamoxifen-associated hot flashes in women

Supportive Cancer Therapy

Volumn 4, Issue 3, 2007, Pages 152-156

  Pérez, Domingo G ^a   Zahasky, Katherine M ^a   Loprinzi, Charles L ^a,c   Sloan, Jeff ^a   Novotny, Paul ^a   Barton, Debra ^a   Pritchard, Kathleen I ^b  

^a Mayo Clinic   (United States)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Fatigue; Menopause

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; INCIDENCE; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; VASOMOTOR REFLEX;

EID: 34547192874     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.009     Document Type: Article

References (15)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998; 339:1609-1618.
2. Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Nat Cancer Inst 1994; 86:527-537.
3. Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA 1980; 243:514-515.
4. Love RR, Cameron L, Connell BL, et al. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991; 151:1842-1847.
5. Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993; 11:29-35.
6. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320:479-484.
7. Love RR, Feyzi JM. Reduction in vasomotor symptoms from tamoxifen over time. J Natl Cancer Inst 1993; 85:673-674.
8. Loprinzi CL, Zahasky KM, Sloan JA, et al. Tamoxifen-induced hot flashes. Clin Breast Cancer 2000; 1:52-56.
9. Sloan J, Loprinzi C, Novotny P, et al. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001; 19:4280-4290.
10. Cohen J. Statistical Power for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
11. Sloan JA, et al. Detecting worms, ducks and elephants: a simple approach for defining clinically relevant effects in quality-of-life measures. J Cancer Int Med 2003; 1:41-47.
12. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20:418-434.
13. Sumner BE, Grant KE, Rosie R, et al. Effects of tamoxifen on serotonin transporter and 5-hydroxitryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Molecular Brain Research 1999; 73:119-128.
14. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 2005; 28:401-416.
15. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001; 52:345-356.